Arterex, Scottsdale, AZ – Arterex, a global medical device contract manufacturer, yesterday announced the appointment of Bill Gerard to the position of president, Arterex North America, which includes Arterex’s Formula Plastics (located in Mexico) and NextPhase Medical (located in MA, NH and Mexico) divisions. Gerard was formerly president of Formula Plastics.
“Delivering innovative solutions has made Formula Plastics an integral part of the medical product supply chain,” said Gerard. “Adding NextPhase and combining the talents of these two organizations will allow us to deliver exceptional value to the medical industry and create synergies that enable us to better serve our combined core of blue-chip medical OEM customers and regional specialty customers.”
The Arterex North America management team will also include Rob Olsen as chief commercial officer of Arterex North America. Olsen has been with NextPhase for more than six years. Prior to this he held senior positions at Flextronics International and Nypro, Inc.
Matt Giza who held the position of NextPhase Electromechanical Medical Device Division (EMD) vice president – general manager, is now senior vice president and general manager of all NextPhase including its Single Use Device (SUD) division.
NextPhase is a class II, III and PMA medical device contract manufacturer of complex electromechanical devices, active implantable devices and single use disposables in North America. It provides design and engineering, manufacturing and assembly, quality and regulatory, and supply chain and logistics management services enabling its customers to bring low-to-medium volume complex medical devices to market.
Formula Plastics focuses on fully integrating molded plastic parts and other manufactured or purchased components into a finished and ready-for-use (sterile or non-sterile) medical device. With quality systems and process validation, it ensures consistent product quality and delivery. Its capabilities include ISO Class 8 assembly and injection molding capacity, plastic joining and decorating technologies, including radio frequency and ultrasonic welding, solvent and UV bonding, and tool design and manufacturing.
All Arterex North American plants are ISO 13485:2016 certified, FDA Registered and include ISO class 8 clean room capacity along with best-in-class LEAN practices.
“Building a global multi-capability medical device contract manufacturing organization takes an industry leading management team,” said Charles Stroupe, Executive Chairman of Arterex, “These management appointments will ensure we take the best advantage of our highly complementary development, manufacturing and assembly capabilities within the Arterex platform. Our proven leaders with deep industry experience execute the Arterex strategy for the benefit of all our customers, staff and stakeholders.”